Recent Updates
Recently added Catalysts

Phase 2 Biotech Catalysts to Watch This Week (June 12–16, 2025)

BiopharmaWatch Research3 min read

Phase 2 Biotech Catalysts to Watch This Week (June 12–16, 2025)

Biotech investors, buckle up. The week of June 12, 2025, is packed with Phase 2 data readouts from small- and mid-cap companies. These upcoming clinical trial results could trigger major stock moves, making this a critical moment for anyone tracking emerging biopharma plays.

Below, we break down six companies set to release Phase 2 trial data this week, the therapies involved, potential market impacts, and where each stands in terms of probability of approval (PoA).

1. Ascentage Pharma (AAPG) – Olverembatinib (HQP1351)

  • Catalyst Date: June 12, 2025
  • Indication: Chronic Myeloid Leukaemia (CML), Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia (Ph+ ALL)
  • PoA: 75%
  • Market Cap: $2.61B

Olverembatinib is a novel third-generation BCR-ABL tyrosine kinase inhibitor targeting resistant forms of CML and Ph+ ALL. With an impressive 75% PoA and a solid market cap, this readout could significantly boost investor confidence if results are positive.

🔗 Internal Link: Check upcoming FDA events

2. Syndax Pharmaceuticals (SNDX) – Revumenib (Revuforj®)

  • Catalyst Date: June 12, 2025
  • Indication: Relapsed/refractory acute leukaemia with NPM1 mutation
  • PoA: 85%
  • Market Cap: $935.77M

SNDX has one of the most promising readouts this week with Revumenib, a selective menin inhibitor. A positive readout could revive bullish sentiment in the hematologic cancer space.

3. BioRestorative Therapies (BRTX) – BRTX-100

  • Catalyst Date: June 13, 2025
  • Indication: Chronic Lumbar Disc Disease (cLDD)
  • PoA: 70%
  • Market Cap: $13.96M

Microcap BRTX is developing a stem cell-based therapy for chronic back pain. With recent price movement and low float, positive data could trigger a rally.

💡 Tip: Monitor volume spikes—this is a classic microcap setup.

4. Connect Biopharma (CNTB) – Rademikibart

  • Catalyst Date: June 13, 2025
  • Indication: Type 2 Asthma (Eosinophilic Driven)
  • PoA: 75%
  • Market Cap: $44M

Anti-IL4Rα monoclonal antibody Rademikibart is being tested in severe asthma, a crowded market. Strong data could spark partnerships.

5. Disc Medicine (IRON) – Bitopertin

  • Catalyst Date: June 14, 2025
  • Indication: Erythropoietic Protoporphyria (EPP)
  • PoA: Not specified
  • Market Cap: $1.77B

Bitopertin targets EPP, a rare photosensitivity disorder. Though PoA isn’t listed, IRON’s valuation shows strong backing.

🔗 Internal Link: Track hedge fund sentiment

6. Upstream Bio (UPB) – Verekitug (IgG1 antibody)

  • Catalyst Date: June 15, 2025
  • Indication: Severe asthma, chronic rhinosinusitis with nasal polyps
  • PoA: 60%
  • Market Cap: $625.08M

Verekitug targets immune responses in asthma. Moderate PoA and upside potential if efficacy aligns with early data.

Honorable Mention: Roivant Sciences (ROIV) – Brepocitinib

  • Catalyst Date: June 17, 2025
  • Indication: Cutaneous sarcoidosis
  • PoA: 30%
  • Market Cap: $7.70B

Brepocitinib, a JAK/TYK2 inhibitor, could unlock a new use case if data in sarcoidosis shows a signal.

Final Thoughts

This week’s Phase 2 readouts offer a goldmine of insights. From rare diseases to common conditions, each catalyst event can reshape stock narratives.

📅 Pro Tip: Add these tickers to your CatalystSync™ dashboard for real-time updates.

Frequently asked questions

What are Phase 2 biotech catalysts?
Phase 2 biotech catalysts refer to key events or data readouts from clinical trials that can significantly impact the stock prices of biotech companies. These catalysts typically involve the evaluation of a drug's efficacy and safety in a larger group of patients, and positive results can lead to increased investor confidence and potential FDA approval.
How do Phase 2 data readouts affect biotech investments?
Phase 2 data readouts can greatly influence biotech investments by causing substantial stock price movements. Investors closely monitor these results as they provide insights into a drug's potential market success and the probability of FDA approval, which can lead to significant financial gains or losses.
Which biotech companies have important Phase 2 catalysts this week?
This week, several biotech companies have important Phase 2 catalysts, including Ascentage Pharma with Olverembatinib for chronic myeloid leukaemia, and Syndax Pharmaceuticals with Revumenib for relapsed/refractory acute leukaemia. Each company has a varying probability of approval, which investors should consider when evaluating potential investments.
What is the significance of the probability of approval (PoA) in Phase 2 trials?
The probability of approval (PoA) is a critical metric in Phase 2 trials, indicating the likelihood that a drug will receive FDA approval based on trial results. A higher PoA suggests stronger data and greater investor confidence, while a lower PoA may indicate higher risks associated with the investment.
When should investors pay attention to Phase 2 biotech catalysts?
Investors should pay attention to Phase 2 biotech catalysts during the weeks leading up to data readouts, as these events can trigger significant stock price movements. Staying informed about the timing of these readouts and the companies involved can help investors make strategic decisions in the biotech sector.